Polaryx Therapeutics, Inc. (PLYX)
NASDAQ: PLYX · Real-Time Price · USD
3.550
+0.810 (29.56%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Polaryx Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
| Selling, General & Admin | 1.58 | 1.54 | 1.01 |
| Research & Development | 6.06 | 2.81 | 2.77 |
| Operating Expenses | 7.63 | 4.35 | 3.78 |
| Operating Income | -7.63 | -4.35 | -3.78 |
| Other Non Operating Income (Expenses) | -0.58 | -26 | 0 |
| Pretax Income | -8.21 | -30.36 | -3.78 |
| Net Income | -8.21 | -30.36 | -3.78 |
| Net Income to Common | -8.21 | -30.36 | -3.78 |
| Shares Outstanding (Basic) | 44 | 34 | 11 |
| Shares Outstanding (Diluted) | 44 | 34 | 11 |
| Shares Change (YoY) | 307.12% | 219.94% | - |
| EPS (Basic) | -0.19 | -0.89 | -0.35 |
| EPS (Diluted) | -0.19 | -0.89 | -0.35 |
| EBIT | -7.63 | -4.35 | -3.78 |
Source: S&P Capital IQ. Standard template.
Financial Sources.